SavedAdd your journal

Journals / Göğüs Kalp Damar Anestezi ve Yoğun Bakım Derneği Dergisi / 2019 / Cilt: 25 - Sayı: 1

ECMO (Extracorporeal Membrane Oxygenation) in Rhabdomyolysis Due to Statin Use

Statin Kullanımına Bağlı Rabdomiyolizde ECMO (Ekstrakorporal Membran Oksijenizasyonu) Kullanımı

Mine ALTINKAYA ÇAVUŞ
Şerife BEKTAŞ
Dilek KAZANCI
Sema TURAN
Pages
68–71
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Despite a successful case shared in the literature, our case lead a mortal course.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 69-year-old woman has been using atorvastatin for 3 years.
📊
Key Findings & Data:ECMO was used in the treatment of multiple organ failure in developing rhabdomyolysis.
💡
Conclusion & Impact:Despite a successful case shared in the literature, our case lead a mortal course.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 69-year-old woman has been using atorvastatin for 3 years. ECMO was used in the treatment of multiple organ failure in developing rhabdomyolysis. Despite a successful case shared in the literature, our case lead a mortal course.

Özet

Altmış dokuz yaşında kadın hasta 3 yıldır atorvastatin kullanmaktadır. Gelişen rabdomiyoliz sonucu çoklu organ yetmezliği tedavisinde ECMO kullanılmıştır. Literatürde paylaşılan başarılı bir olguya rağmen, olgumuz mortal seyretmiştir.

🔖

Cite This Article

ÇAVUŞ, M. A., BEKTAŞ, Ş., KAZANCI, D., TURAN, S. (2019). ECMO (Extracorporeal Membrane Oxygenation) in Rhabdomyolysis Due to Statin Use. Göğüs Kalp Damar Anestezi ve Yoğun Bakım Derneği Dergisi, Cilt: 25 - Sayı: 1, 68–71. https://ajindex.com/articles/194070

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ferah I, Avşar Ü, Albayrak A. Are statins reliable drugs as mentioned? Indications and risks for statins. J Clin Anal Med. 2014;5(4):341-6.
  2. Endo A. Theorigin of thestatins. Atheroscler Suppl. 2004;53(3):125-30.
  3. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, et al. Statin safety: an assessmentusing an administrative claims database. Am J Cardiol. 2006;97(8A):61-8.
  4. Baek SD, Jang SJ, Park SE, Ok TJ, Leem J, Lee HS, et al. Fatal rhabdomyolysis in a patient with liver cirrhosis afte rswitching from simvastatin to fluvastatin. J Korean Med Sci. 2011;26:1634-7.
  5. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med. 2009;11:272-8.
  6. Akoglu H, Yilmaz R, Kirkpantur A, Arici M, Altun B, Turgan C. Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure. Ann Pharmacother. 2007;41:143-7.
  7. Joy TR, Hegele RA. Narrative review: statin-relatedmyopathy. Ann Intern Med. 2009;150:858-68.
  8. Russo MW, Jacobson IM. How tousestatins in patients with chronic liver disease. Cleve Clin J Med. 2004;71:58- 62.
  9. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord. 2014;24:4-15.
  10. Paiva H, Thelen KM, Van CR, Smet J, De PB, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial. Clin Pharmacol Ther. 2005;78:60-8.
  11. Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, et al. Simvastatin effects on skeletal muscle: Relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol. 2013;61:44-53.
  12. Ramachandran R, Wierzbicki SA. Statins, muscle disease and mitochondria. Journal of Clinical Medicine 2017;6(8):75
  13. Augustin SL, Horton S, Thuys C, Bennett M, Claessen C. Brizard theuse of extracorporeal life support in thetreatment of influenza-associated myositis/rhabdomyolysis C. Perfusion. 2006;21(2):121-5. https://doi.org/10